Radiopharm Theranostics (ASX:RAD) has announced a Share Subscription Agreement and a Share Purchase Agreement to provide initial funding of $1.5 million and total funding of up to $12.5 million with Lind Global Fund II LP.
Lind is an entity managed by New York-based The Lind Partners that invests in small and mid-cap companies publicly traded in the US, Canada, Australia and the UK.
Radiopharm managing director Riccardo Canevari said, “We are pleased to have entered these arrangements with Lind and look forward to a mutually beneficial relationship. The funds will support our ongoing clinical trials programs.”
Phillip Valliere, the managing director of The Lind Partners, said, “Lind is pleased to invest to support Radiopharm’s mission of becoming a recognised leader in radiopharmaceutical products for therapeutic and diagnostic applications. We are pleased that the Board has chosen Lind as a financial partner to advance Radiopharm’s clinical and commercialization efforts.”